# Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma

> **NCT00559455** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 38 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT00559455
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559455, "Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00559455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*